SCHEMBL5192967

SCHEMBL5192967

CCCc1ccc(O)c(O)c1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.59
PTPN1 P18031 3/20 0.54
PTPN11 Q06124 2/20 0.54
BID P55957 6/20 0.49
MCL1 Q07820 6/20 0.49
BCL2L1 Q07817 5/20 0.49
BAK1 Q16611 5/20 0.49
KAT8 Q9H7Z6 3/20 0.49
EP300 Q09472 2/20 0.49
KAT5 Q92993 2/20 0.49
SAE1 Q9UBE0 2/20 0.49
PPARG P37231 1/20 0.49
PPARA Q07869 1/20 0.49
KAT2A Q92830 1/20 0.49
KAT2B Q92831 1/20 0.49
PTPN2 P17706 1/20 0.43
MMP2 P08253 2/20 0.42
F7 P08709 2/20 0.42
F3 P13726 2/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5194899 0.89 BID (0.58) PRKCIBIDMCL1BCL2L1BAK1
SCHEMBL5675080 0.88 BID (0.65) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5676741 0.86 PRKCI (0.46) PRKCIPTPN1PTPN11BIDMCL1
SCHEMBL5586821 0.86 BID (0.68) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5587592 0.86 BID (0.68) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL8674815 0.85 PRKCI (0.74) PRKCIPTPN1PTPN11BIDMCL1
SCHEMBL5586741 0.81 SELL (0.39) PRKCIPTPN1PTPN11BIDMCL1
SCHEMBL5587917 0.81 SELL (0.39) PRKCIPTPN1PTPN11BIDMCL1
SCHEMBL5589102 0.81 SELL (0.39) PRKCIPTPN1PTPN11BIDMCL1
SCHEMBL5590599 0.81 SELL (0.39) PRKCIPTPN1PTPN11BIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4114960-A2 PRENYLTRANSFERASES AND METHODS OF MAKING AND USE THEREOF Cellibre, Inc. (US) 2023-01-11 EP disclosed
WO-2021178976-A2 PRENYLTRANSFERASES AND METHODS OF MAKING AND USE THEREOF CELLIBRE, INC. (US) 2021-09-10 WO disclosed
WO-2019053541-A1 ACRYLATES THROUGH OLEFIN/CARBON DIOXIDE COUPLING SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2019-03-21 WO disclosed
WO-2019053540-A1 METHODS OF PRODUCING ALPHA, BETA-UNSATURATED CARBOXYLIC ACID SALTS FROM ALKANES AND CARBON DIOXIDE SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2019-03-21 WO disclosed
WO-2017158469-A1 METHODS OF MAKING ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS OR SALTS SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2017-09-21 WO disclosed
EP-1620447-B1 SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III EXXONMOBIL CHEM PATENTS INC (US) 2007-08-08 EP disclosed
US-7067450-B2 Soluble late transition metal catalysts for olefin oligomerizations III EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-06-27 US disclosed
US-20060036049-A1 Soluble late transition metal catalysts for olefin oligomerizations III ZHAO BAIYI 2006-02-16 US disclosed
EP-1620447-A1 SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III Exxonmobil Chemical Patents Inc. (US) 2006-02-01 EP disclosed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP disclosed
US-20040044150-A1 Soluble late transition metal catalysts for olefin oligomerizations III EXXONMOBIL CHEMICAL PATENTS INC. 2004-03-04 US disclosed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO disclosed
WO-2003102006-A1 SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III EXXONMOBIL CHEMICAL PATENTS INC. (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060036049-A1 Soluble late transition metal catalysts for olefin oligomerizations III COMT, CD69, SPR PRKCI 4096/4885PTPN1 4673/4885PTPN11 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.